Block Grant R43AI074216

Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...

Summary Georgia TECH Research Corp received a $725,241 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 2, 2026, with completion targeted for January 31, 2031. The award supports research and development of controlled-delivery HIV vaccine candidates utilizing advanced immunological and pharmaceutical technologies. The project integrates five core components: injectable...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $364,167 to Villanova University to develop novel non-viral gene delivery methods for cell therapies. The key objectives are: The Bracaglia Lab will develop new polymeric gene delivery vehicles to improve the delivery of siRNAs and other payloads to T cells and hematopoietic stem cells (HSCs). Drs. Elmer and Huang will...

Grant Award Summary Gateway Bio Inc. received a $628,694 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 23, 2025, with completion targeted for August 31, 2026. The project focuses on developing a next-generation lipid nanoparticle (LNP) delivery system utilizing poly(oligoethylene glycol) methyl ether methacrylate (POEGMA)—a proprietary polyethylene glycol (PEG)...

Federal Project Grant Award Summary Orlance, Inc. received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 11, 2025, with completion targeted for August 31, 2027. The award supports development and advancement of a therapeutic nucleic acid vaccine for chronic hepatitis B (CHB) in HIV/hepatitis B virus (HBV) co-infected individuals. Orlance will...

Federal Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 11, 2025, with completion targeted for August 31, 2027. The awardee is developing a microneedle-based messenger RNA (mRNA) flu vaccine for transcutaneous (skin-based) immunization. The project leverages Via Therapeutics' proprietary thin-film...

Grant Award Summary Children's Mercy Hospital received a $433,175 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. The award supports the development of a mosaic messenger ribonucleic acid (mRNA) vaccine designed to prevent hand, foot, and mouth disease (HFMD) caused by human enterovirus A viruses. The research deliverables include the design...

Federal Project Grant Award Summary Massachusetts General Hospital received a $676,666 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 3, 2025, with a completion date of August 31, 2030. The award funds research into spatial and temporal adjuvant delivery mechanisms designed to enhance messenger RNA (mRNA) vaccine efficacy and durability. The project will...

Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective July 1, 2025, through June 30, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project focused on developing Stable Prophylactic Antibodies (SPABs) that maintain efficacy over extended periods. The primary deliverable is the creation of enhanced antibody mutations that significantly...

Souvie Biodelivery LLC received a $225,000 Project Grant award from the National Science Foundation Division of Industrial Innovation on February 15, 2021 to develop a novel drug delivery system using engineered exosomes. The award is part of NSF's Engineering program (CFDA 47.041), which seeks to improve quality of life and economic strength through engineering research and innovation. Under the award, Souvie Biodelivery will work to advance its exosome-based drug delivery platform technology...